[citation needed] In 2017, the ONCOCHECK project, which involves a series of clinical studies focused on cancer diagnostics, received €3.1 million in funding from the European Union's Horizon 2020 research and innovation program.

In 2022, the company's prostate cancer diagnostic tool received approval from the Spanish Agency for Medicines and Health Products (AEMPS).

Subsequently, they either undergo a process called apoptosis (cells progressively die) or go into senescence (they lose their function).

Due to the impact, they have at the cellular level, the length of telomeres and their rate of shortening is considered a relevant biomarker for assessing the state of aging of the entire organism.

With more than 7,000 peer-reviewed scientific and clinical publications, telomere length measurement has established itself as a biomarker in cancer diagnosis and prognosis.

Within the ONCOCHECK project, Life Length is also conducting studies in advanced solid tumors and chronic lymphocytic leukemia (CLL).

[citation needed] This diagnosis is an in vitro diagnostic test (IVD) that makes it possible to identify patients with a higher risk of suffering from aggressive prostate cancer.

With its telomere measurement platform, the test could potentially fill the gap in lung cancer screening techniques in a routine, minimally invasive, and low-cost way.

The aim of the study was to help oncology and hematology specialists make better decisions and increase the chances of these children beating cancer.

[citation needed] License: The center of Health Facilities and Regulation authorized Life Length to conduct and maintain an Out of State Clinical Laboratory in conformity with RIGL C23-16.2.